Blog

  • The Trump administration has halted funds for global HIV/AIDS programs. No one knows how big the impact is

    The Trump administration has halted funds for global HIV/AIDS programs. No one knows how big the impact is

    The United States has suspended some funding for its flagship AIDS relief program, according to international organizations and members of Congress who warn the cuts are already hurting patients and halting critical projects globally.

    The full extent of the budget cuts related to US-funded HIV/AIDS relief work is highly unclear, and Congress is still battling the White House’s proposed budget clawbacks and withholding of billions of dollars in funding.

    PEPFAR, formally called the US President’s Emergency Plan for AIDS Relief, is credited with saving more than 26 million lives over the past two decades and preventing millions of HIV infections, particularly in Africa.

    Last year alone, government figures show that PEPFAR provided 20.6 million people with life-saving HIV medicines, called antiretroviral therapy. It also supported more than 342,000 health workers to deliver HIV treatments, prevention care and support services, bolstering healthcare systems in more than 50 countries.

    Funding for the landmark program – established in 2003 by the Bush administration – was primarily implemented by USAID, which US President Donald Trump dismantled earlier this year after a freeze on foreign aid. The US State Department later issued a waiver to exempt life-saving services from that freeze, including those of PEPFAR, and moved operations to the State Department’s remit.

    But nonprofits are sounding the alarm that HIV/AIDS projects have been terminated regardless. And without USAID, implementation of many planned initiatives has also stalled. Such cuts are severely disrupting patients’ medical care across Africa, Asia and Latin America, threatening the global fight against the disease, they say.

    An aerial view of Migosi Sub-county Hospital in Kisumu, Kenya, where the continuity of services for thousands of HIV patients has been threatened. – Michel Lunanga/Getty Images

    How is HIV/AIDS relief work being impacted?

    UNAIDS, the United Nations’ agency working to end AIDS, has cited examples around the world of medicine stockouts, staffing cuts at HIV/AIDS clinics, suspended community outreach services and “rising levels of stigma, discrimination and mortality rates” in the wake of the US funding cuts.

    The suspensions have caused major disruptions to HIV responses in dozens of countries, including Uganda, the Philippines and Tanzania, the UN agency said.

    People living with HIV are skipping and rationing doses of antiretroviral medications, creating conditions for drug-resistant HIV strains to emerge, according to the nonprofit Physicians for Human Rights, which compiled testimonies of healthcare disruptions from people in Tanzania and Uganda.

    Doctors Without Borders has warned that “PEPFAR faces an uncertain future” and that project cancellations following the dismantling of USAID have already impacted humanitarian work.

    “PEPFAR’s scope of work has already been dramatically reduced since January when the State Department restricted its work on key areas of HIV prevention, treatment, care, and support,” the Doctors Without Borders statement said, contradicting the US government’s repeated claims that lifesaving aid work is being preserved.

    “Cuts are not just hitting program activities and medical stocks; they are crippling the logistical backbone of HIV care. Transport for distributing supplies has all but vanished,” said the organization’s representative in Zimbabwe, Zahra Zeggani-Bec.

    Children play on a trampoline at the Nyumbani Children's Home in Kenya, which cares for more than 100 children with HIV, whose parents died of the disease, while providing them with US-funded supplies of antiretroviral medicines. - Thomas Mukoya/Reuters

    Children play on a trampoline at the Nyumbani Children’s Home in Kenya, which cares for more than 100 children with HIV, whose parents died of the disease, while providing them with US-funded supplies of antiretroviral medicines. – Thomas Mukoya/Reuters

    World Vision, an international Christian organization focusing on poverty and development, told CNN it had a large PEPFAR program in Kenya that had been terminated.

    “That (program) had focused primarily on orphans and vulnerable children and prevention activities,” said Margaret Schuler, World Vision’s chief impact officer. Shuler said it was surprising that “what would have been considered ‘lifesaving programs’ were terminated,” including other World Vision programs related to health care and disease control.

    Full extent of impact is unknown

    PEPFAR reporting data has been publicly unavailable for months, meaning there’s little clarity on the program’s ongoing activities. A message on the government website says it is “undergoing updates.” The release dates for 2025 PEPFAR data reports are all listed as “TBD.”

    A State Department spokesperson told CNN that “data collection is ongoing to capture recent updates to programming.”

    UNAIDS said in a report in April that, among 70 of its country offices, 28 (40%) had witnessed an end to community-led services due to the US funding cuts. Meanwhile, 21 (30%) reported that services by international NGOs had been stopped.

    Some of that work may have resumed, but it’s impossible to determine how much, given the lack of data on the budget, contracted services and “what has actually been delivered,” said Charles Kenny, a senior fellow at the Center for Global Development, a think tank based in the US and UK.

    He wrote in an analysis of the status of US aid operations that “right now, Congress and taxpayers have no visibility on what the foreign assistance system is trying to accomplish, let alone if that is happening.”

    Antiretroviral medication is dispensed at TASO Mulago service center in Kampala, Uganda, on February 17, 2025. - Hajarah Nalwadda/Getty Images

    Antiretroviral medication is dispensed at TASO Mulago service center in Kampala, Uganda, on February 17, 2025. – Hajarah Nalwadda/Getty Images

    Secretary of State Marco Rubio has stated PEPFAR is an important and life-saving program that will continue, a State Department spokesperson told CNN, adding that Rubio has “also said that PEPFAR, like all assistance programs, should be reduced over time as they are impactful in achieving their mission.”

    Last week, the State Department announced a joint commitment with the Global Fund to purchase the drug lenacapavir, an HIV prevention injection that only has to be taken twice a year, from the American biopharmaceutical company Gilead Sciences. PEPFAR will distribute the drug in eight to 12 high-burden HIV countries in 2026, with a focus on reducing the number of new HIV infections in pregnant and breastfeeding mothers, according to a State Department statement.

    What is happening with the Congressional budget battle?

    The White House Office of Management and Budget (OMB) has released only about half ($2.9 billion) of the $6 billion appropriated by Congress for PEPFAR’s 2025 funding, according to budget documents on a nonprofit website that tracks the OMB.

    A congressional aide raised concerns that the budget document listed billions of dollars of this year’s funds as part of fiscal year 2026, which the aide described as atypical.

    A budget expert told CNN that the 2025 PEPFAR apportionment looks “weird” compared to previous years’ documents, which typically specify how much money is going to each government department involved in PEPFAR. For this year, the released funds are listed as “unallocated” and conditional on a spending plan that has to be agreed upon by OMB and the State Department. Those spending plans are not publicly available.

    The source also said that placing the funds into fiscal year 2026 is at least an indication that OMB is not willing to spend the PEPFAR money now, and it could be an attempt to “slow walk” the funding.

    Another congressional aide told CNN that Congress doesn’t have a clear picture because of a lag time in the information the White House must report to the public. It’s possible that 2025 funding could still be released in the coming weeks and months.

    The picture of funding flows remains fuzzy, and it comes after the Trump administration already tried to claw back $400 million for PEPFAR. That proposal was canceled after bipartisan opposition in the Senate. Yet not all of those funds had been released, top Senate appropriator Susan Collins, a Republican from Maine, told CNN in a statement last week.

    “OMB is blocking funding for PEPFAR, one of the most successful global health programs in history,” Collins said. “PEPFAR funds are simply not reaching those in need, as confirmed by those in the field.”

    The ranking Democrat on the Senate Appropriations Committee, Senator Patty Murray of Washington, has called out OMB Director Russell Vought directly, saying that “even after promising Republican lawmakers that the program would be protected, he’s choked off a huge chunk of funding provided by Congress for PEPFAR.”

    “The law is clear as day: the full funding Congress provided must be used for the work PEPFAR does day in and out. The more these funds are obstructed and delayed, the more people will die needlessly,” Murray told CNN in a statement.

    CNN has reached out to OMB for comment but has not received a response.

    Another fight brewing over foreign aid

    Separately, last week, Trump notified Congress he was moving to cancel $4.9 billion in foreign aid already approved for this year, drawing criticism from lawmakers from both parties who questioned the legality of the move. The US Government Accountability Office says rescissions so late in the fiscal year are illegal.

    Last Wednesday, a federal judge ruled that without congressional approval, the administration can’t decide to withhold federally budgeted foreign aid money that will expire at the end of this month.

    But the White House is mounting a multi-front effort to do so both in the courts and on Capitol Hill, with Trump asking the Supreme Court on Monday to step back into the fight.

    CNN’s Sarah Ferris, Jennifer Hansler and Katelyn Polantz contributed to this report.

    For more CNN news and newsletters create an account at CNN.com

    Continue Reading

  • Vascular Involvement in Behçet’s Disease: Diagnostic Value and Clinical Implications

    Vascular Involvement in Behçet’s Disease: Diagnostic Value and Clinical Implications


    Continue Reading

  • Facebook’s settlement payments are going out. Here’s what to expect

    Facebook’s settlement payments are going out. Here’s what to expect

    Facebook users who filed a claim in parent company Meta’s $725 million settlement related to the Cambridge Analytica scandal may soon get a payment.

    It’s been over two years since Facebook users were able to file claims in Meta’s December 2022 settlement. The class-action lawsuit began after the social media giant said in 2018 that as many as 87 million Facebook users’ private information was obtained by data analytics firm Cambridge Analytica, which had worked with President Donald Trump’s 2016 campaign.

    Meta was accused of allowing Cambridge Analytica and other third parties, including developers, advertisers and data brokers, to access private information about Facebook users. The social media giant was also accused of insufficiently managing third-party access to and use of user data.

    Meta did not admit wrongdoing as part of the settlement. Following the Cambridge Analytica incident, Facebook restricted third-party access to user data and “developed more robust tools” to inform users about how data is collected and shared, according to court documents.

    Here’s what you need to know about the settlement payments.

    Any US Facebook user who had an active account between May 24, 2007, and December 22, 2022, was eligible to file a claim, even if they have deleted the account.

    The deadline to file was August 25, 2023. Almost 29 million claims were filed and about 18 million were validated as of September 2023, according to Meta’s response in a 2024 legal document.

    According to the settlement site, payments would be determined by whether a claim was valid and “how long you were a user on Facebook” between .May 24, 2007 and December 22, 2022. Those who did not file a claim are ineligible to receive a payment.

    Two appeals were filed after the settlement that were not resolved until May 14, 2025, according to the settlement site.

    The settlement was finalized on May 22, 2025, and on August 27, the court ordered that settlement benefits be distributed.

    “The distribution of settlement benefits has commenced and will continue for approximately 10 weeks. We thank you in advance for your patience,” according to the site’s September 3 update.

    Approved claims are notified by email up to four days before their payouts are issued.

    Anyone who is unsure about the status of their claim can contact the settlement administrator at info@facebookuserprivacysettlement.com, with their claim ID.

    Of the $725 million settlement fund, roughly $540 million will cover approved settlement claims.

    According to the settlement plan, a system of “allocation points” will determine payments. One allocation point is assigned for each calendar month a person had a Facebook account between May 24, 2007, and December 22, 2022.

    “Class members who were active on Facebook longer, and who therefore may have more valuable claims, will receive a larger share of the settlement,” Meta said in the 2024 legal document.

    Payments will either be sent directly to the bank account provided on the claim form, or via PayPal, a virtual prepaid Mastercard, Venmo or Zelle. Unsuccessful or expired payments will receive a “second chance email” to update the payment method.


    Continue Reading

  • Why generic ‘extracurriculars’ are no longer enough in competitive global admissions

    Why generic ‘extracurriculars’ are no longer enough in competitive global admissions

    A laundry list of clubs and short-term volunteering say little without leadership or measurable outcomes. 
    | Photo Credit: Getty Images/iStockPhoto

    For many years, Indian students aspiring to study at top global universities were advised to participate in as many activities as possible. Play a sport, join a debate club, volunteer … show you’re “well-rounded.” However, admissions to the world’s best schools do not work like that anymore. Competition is fiercer and applicant pools are brimming with talent, so simply listing random activities risks diluting a student’s true potential. Now, what matters is real depth, genuine passion, meaningful leadership, and impact you can see.

    This shift owes much to a broader change in how leading institutions teach. At several top U.S. universities, undergraduates are encouraged to dive into hands-on, project-based learning from day one. Early access to innovation labs and entrepreneurship centres helps students discover their true interests and develop real-world skills, long before they write their first application.

    Personal impact

    Admissions teams aren’t counting activities or hours. They ask what those experiences meant to you, where you took initiative, and what impact you achieved. Starting a project or sustaining commitment in one or two areas shows growth, responsibility, and deeper learning. For instance, a student who volunteers weekly at a local health clinic or spearheads a community coding workshop over several years stands out far more than one who joins dozens of clubs briefly. Admissions panels also value roles that connect to academic passions: high-school research, interdisciplinary projects, or efforts that earn external recognition, such as awards or publications. These elements of initiative, depth, impact, and intellectual engagement form the core of a stand-out profile.

    Yet as the drive to impress grows, many students fall into the trap of crafting “over-calculated” profiles: strategically stacking activities to tick admissions office boxes. In rare cases, it can work but, more often, it backfires; inauthentic narratives are easily spotted and seldom compelling. Moreover, students who chase trending topics without genuine interest end up with disjointed stories that undermine academic focus. Instead, honest reflection on personal passions should inform every choice, transforming participation into memorable narratives grounded in real challenges and achievements.

    Generic advice about “doing more” often misfires. A laundry list of clubs and short-term volunteering say little without leadership or measurable outcomes. While admirable, brief involvement cannot convey the problem-solving depth gained from tackling complex issues over months or years. Without proper guidance, opportunities to elevate simple activities into impactful, story-worthy projects are lost.

    Begin early

    A more strategic approach begins early and focuses on authentic interests. Identify causes or problems that resonate personally, then choose one or two areas for long-term commitment, taking on greater responsibility as you progress. Seek mentored experiences, structured projects, or internships with expert guidance to gain practical skills and produce concrete results. Guidance from educators, industry experts, or research supervisors is invaluable to refine projects and maximise impact. Document obstacles, solutions found, skills learned, and outcomes, which will fuel confident essays and interviews and show exactly how real-world work ties into academic goals. For example, a mentored robotics internship that culminates in a working prototype can demonstrate abilities far more vividly than a dozen brief club entries.

    Data from recent application cycles reinforces this model. Over 70% students admitted to their first- or second-choice universities demonstrated sustained involvement of 2-3 years more in a single passion or project. Across disciplines, STEM, humanities, and arts, this pattern holds: depth beats breadth. Those who could point to clear results or recognition saw acceptance rates nearly double compared to peers with more scattered résumés.

    Gaining entry to leading global universities today requires a thoughtful, focused strategy highlighting genuine commitment, leadership, measurable impact, and authentic passion. Admissions committees will remember those with a clear vision and proven dedication, as such applicants bring bring curiosity, resilience, and a track record of real-world problem solving. This reflective, passion-driven approach is no longer optional. It’s essential.

    The writer is co-founder and CEO, Application Ally and BuildUp.

    Continue Reading

  • ‘I’ve seen so many people go down rabbit holes’: Patricia Lockwood on losing touch with reality | Patricia Lockwood

    ‘I’ve seen so many people go down rabbit holes’: Patricia Lockwood on losing touch with reality | Patricia Lockwood

    There is a thing Patricia Lockwood does whenever she spots a priest while walking through an airport. The 43-year-old grew up as one of five children of a Catholic priest in the American midwest, an eccentric upbringing documented, famously, in Priestdaddy, her hit memoir of 2017, and a wellspring of comic material that just keeps giving. Priests in the wild amuse and comfort her, a reminder of home and the superiority that comes with niche expertise. “I was recently at St Louis airport and saw a priest,” she says, “high church, not Catholic, because of the width of the collar; that’s the thing they never get right in TV shows. And I gave him a look that was a little bit too intimate. A little bit like: I know.” Sometimes, as she’s passing, she’ll whisper, “encyclical”.

    This is Lockwood: elfin, fast-talking, determinedly idiosyncratic, with the uniform irony of a writer who came up through social media and for whom life online is a primary subject. If Priestdaddy documented her unconventional upbringing in more or less conventional comic style, her novels and poems since then have worked in more fragmentary modes that mimic the disjointed experience of processing information in bite-size non sequiturs. In 2021, Lockwood published her first novel, No One Is Talking About This, in which she wrote of the disorienting grief at the death of her infant niece from a rare genetic disorder. In her new novel, Will There Ever Be Another You, she returns to the theme, eliding that grief with her descent into a Covid-induced mania, a terrifying experience leavened with very good jokes. A danger of Lockwood’s writing is that it traps her in a persona that makes sincerity – any statement not hedged and flattened by sarcasm – almost impossible. But Lockwood, it seems to me, has a bouncy energy closer to an Elizabeth Gilbert than a Lauren Oyler or an Ottessa Moshfegh, say, so that no matter how glib her one-liners, you tend to come away from reading her with a general feeling of warmth.

    So it is in person, too. Lockwood is speaking with me from her home in Savannah, Georgia, where she lives with her husband, Jason. In 2019, the pair took a vacation to Scotland, accompanied by her mother, providing Lockwood with the opening tour de force of the new novel. Entitled Fairy Pools, this section is a fictionalised travelogue in which the family bicker in the car and enjoy misunderstandings with the Scots, in the form of her mother’s persistent and doomed efforts to order iced tea. There is a long, satisfying run of jokes about how Irn-Bru strikes the American palate (“a pink electrocution of the tongue”). The Lockwood character gets food poisoning. (“Arugula, she thought. I’m going to die alone in a Scottish castle because people have gotten too good for iceberg lettuce.”) They take photos. (“Upon her arrival, instead of taking pictures of the North Sea, she had taken pictures of elk bellowing on the walls and a little guy who appeared to be penetrating his bagpipes.”) And there is a touching vignette based on Lockwood’s sister losing her phone, containing thousands of photos of her late niece, Lena. “You know that the images are backed up,” says Lockwood, now. “But it’s not the original phone. People have these very warm, entangled relationships with these devices as storing memories.”

    All of which is precursor to the main event of the novel, a section entitled The Changeling in which the Lockwood character gets Covid very early on in the pandemic and descends into a state that strikes her as akin to madness, a wordless fog in which intense, random thoughts take on outsized meaning. For example: “It’s like Joyce Carol Oates is trying to start a feud with me … does everyone have this feeling?” Or: “I was glad God had killed Gene Kelly.” It was this experience, says Lockwood, that sparked the novel, which grew out of The Changeling’s first lines: “It stole people from themselves. You might look the same to others but you have been replaced.”

    The challenge for any writer looking back on 2020 at this relatively short distance is that nobody much wants to revisit it. Lockwood was acutely conscious of this and while there are some people in masks in the book, she strenuously avoids use of the words “Covid” and “lockdown”. She hopes that her period of derangement works both as a literal account of a widely experienced phenomenon, and more generally as the book’s guiding metaphor, a stand-in for any life event that causes one to lose contact with reality. And in fact, in early readings, she says, “what seems to be true of audiences is that they recognised all of what I was talking about – even if they hadn’t been ill. I also found it interesting that people were so ready to talk about it when it was something that was like: Hey, ‘Close the curtains, do not write about this, we do not need to think about this again,’ which is what happened with the original flu pandemic [in 1918].”

    I have to confess to Lockwood that words like “changeling” and “fairies” in this context make me extremely nervous. “Do tell!”, she says, gamely. It’s the suggestion of whimsy that sets me off, all the way up to Hilary Mantel’s ghost on the stairs or Muriel Spark’s insistence on believing in angels. Like, sure, OK. But really? Lockwood laughs. “I think you would probably believe in angels too if you could write the way Muriel Spark did” – a fair point. But the difficulty for any writer going the changeling-and-fairy route is to stop the story floating away into figurative affectation, even as she tries to evoke literal feelings of unreality.

    The fact is, says Lockwood, that her sense of being dislocated from herself during Covid was very real. “There are visual, optic aura-type phenomena that I would experience early on, where you would see strange after-images, or a beating in the corner of your eye – things like that. I think people who have those things learn to live with them and make companions out of them and give them names. But this governing phenomenon has no name to [the character]. She doesn’t know what it is. So she’s only experiencing the sensations, the patterns, the colours, the visions. And the true thing, when it feels like madness, is that there’s no name for it.”

    As I was reading, those passages reminded me of a line of Alice Munro’s in which, wrote Munro, everything became “a spiteful imitation of itself”. “Yes,” says Lockwood, “that’s very resonant. Did someone come into my house in the middle of the night and replace everything with a slightly less genuine version? It felt like my eyesight changed, like I was seeing things in less dimensionality, which leads to suspicion. These secret nursed hatreds: like, if I’m not I, are you, you? What is a person?”

    These inquiries of Lockwood’s are presented in a high comic style that saves them from too much abstraction. “For three weeks straight,” she writes, “I have nightmares about being asked about cancel culture. It is my greatest fear, to be asked about cancel culture – or that I will be so terrorized by the possibility that I will immediately begin talking about it anyway, and in doing so present the opportunity to be murdered by public opinion myself.”

    This riff falls in a section in which the protagonist goes on a virtual book tour and endures a photoshoot, all the while freaking out not just about Covid but about exposure. “What she’s experiencing is success, actually, but she’s terrified,” says Lockwood. “Is this what success is? It feels more dysphoric than anything you’ve experienced. In any publicity experience you felt very exposed, but more so because of the extreme cloistered-ness of what everyone was experiencing. Everyone pouring their eyes and their faces into these screens.” One can take this point while also vaguely wishing that novelists might heed the following warning: if you’re tempted to write about going on a book tour, it might be time to venture out beyond publishing to refill the tank.

    Anyway, Lockwood is obviously writing about herself and the disorienting experience both of the success of Priestdaddy, which won the 2018 Thurber Prize for American Humor, and the viral success of her earlier writing; namely, the poem Rape Joke, published by the Awl in 2013, that launched her career, and her subsequent years at the coalface on Twitter, making very good jokes and sharing her comic poetry. (Her most famous sext-parody: “I am a Dan Brown novel and you do me in my plot-hole.”) She’s off Twitter, now, like everyone else. “For a while I did Bluesky, which I liked a lot, and a lot of the original people from Twitter went there.” But as the platform grew, she says, “it had a problem with disagreement bots; you would post something, it would get traction and waves of not-people would be like, ‘I take issue with this!’ That made things less fun.” When Trump was re-elected, she decided she wasn’t going to spend the next four years immersed in online discourse about it and bailed.

    In some ways, says Lockwood, it was her first novel, No One Is Talking About This, shortlisted for the Booker prize in 2021, that proved more exposing than the memoir, because she wrote about her niece, Lena. Lockwood holds up her phone to show me a photo of a baby girl with a shock of brown hair, encumbered by medical equipment. Lena, who was born with Proteus syndrome, died in 2019 at the age of six months. In the years since, Lockwood has written very evocatively about grief. “I saw it secondhand with my sister, and then experienced it myself – that it doesn’t get better. It doesn’t heal. You think, OK, a year has passed, and now progress is going to happen. There won’t be stops and starts, you won’t fall back. You’ll continue to have dreams of this person. And you don’t. There’s this thing that everyone else in the world expects you to move on; like, hurry up already. And that’s not how it happens.”

    Lockwood describes herself as the sort of ‘impulsive person who will steal a police horse in the night’. Photograph: Anna Ottum

    In the case of the death of a baby, she says, there’s even less patience for the grieving parent in some ways; a sense that “she lived for six months and a day, and that’s such a short time upon this Earth there’s a commensurate idea that after six months have passed maybe [things get better].” But that’s not how it goes. Six years after Lena’s death and all that has happened is that “in the mother’s mind, now she’s six years old”.

    Lockwood’s broader writing about her family has given us one of the great, dysfunctional households in literature, up there with David Sedaris’s rackety crowd. Her father, Greg, a former submariner turned Lutheran minister, converted to Catholicism and had a dispensation from the Vatican to be a priest with a wife and children. The five Lockwood kids grew up in rectory accommodation in Cincinnati, Ohio and St Louis, Missouri with a father who liked guns, electric guitars and Rush Limbaugh, as well as God. While her father is inadvertently hilarious but has “never knowingly said anything funny in his life”, her mother, Karen, says Lockwood, “really really knows the joke is funny. She’s a big wordplay person, which I did not inherit! I actually have almost a pun deafness. Someone will present me with a pun and I’ll just stare at them. You tune out your mother as a teenager – ‘Oh, God, mom’ – and it ended with me being completely unable to produce a good pun of any kind.”

    Surprisingly, Lockwood says she is the most conventional of the siblings. Despite describing herself as the sort of “impulsive person who will steal a police horse in the night”, in the context of the family, “everyone would say I’m the most normal. Writing [everything] down is kind of a normie thing to do. In an age in which we have suffered the desaturation of the personality, where we all sound a little bit more the same and colours are more muted, we’ve got some freaks over here among the Lockwood children.”

    This is particularly true of her father, a Trump supporter whom Lockwood has tried to view generously as the victim of Maga’s mass manipulations. In a London Review of Books diary recently she wrote about visiting her parents, “and seeing a Trump flag hanging in the alcove of the rectory, which is not a thing you’re allowed to do in the rectory!” she exclaims. But, she says, “I also had to look at this as something that has happened to a lot of people his age. I’ve seen so many people disappear down rabbit holes of every variety, believe incredibly strange things, that I think we do have to keep our eyes on the ball and look at the propaganda machine – look at the people who are doing this. Who benefits, right? From us being driven from the bosoms of our families because of these nursed hatreds that don’t even make immediate sense?” She says, “I didn’t want it to be true of anyone except this extremely eccentric, idiosyncratic man, right? But what happens when it’s a wave and the wave is overtaking the entire world?”

    The only recourse for the writer is to expose the fundamental absurdity of these people, a role Lockwood is happy to assume. “I think of the clown as the sacrificial role, the one who’s willing to be a fool and to state the thing that everyone else in the room agrees goes unstated. You take that a little bit on yourself so that other people can cohere around you and have a better time.”

    On which subject, I have to ask. At the height of her Covid-induced delusions, what exactly was her beef with Gene Kelly? She laughs. “Oh, that he swept through dance in this muscular way and was like: dance teachers are too feminine, and I’m going to bring masculinity into the world of dance!” This is the joy of a Lockwood rant; a wild jag jumping off from a kernel of truth. During her Covid collapse, the real measure of how far she had drifted from common reality wasn’t Gene Kelly or Joyce Carol Oates but another insidious, heretical thought. She whispers it: “Maybe Meryl Streep isn’t as good as people are saying?” My hand flies to my mouth. “Right? What is a human being if we don’t believe that Meryl Streep can accurately convey a character? Like, where even are you?” Her eyes widen with shock and amusement. “Out of the world.”

    Will There Ever Be Another You by Patricia Lockwood is published by Bloomsbury. To order a copy go to guardianbookshop.com. Delivery charges may apply.

    Continue Reading

  • Durable Control of Multi-Refractory HBV-HCC with Bevacizumab/Sintilima

    Durable Control of Multi-Refractory HBV-HCC with Bevacizumab/Sintilima

    Introduction

    Hepatocellular carcinoma (HCC) is a major global health challenge and ranks as the third leading cause of cancer-related death worldwide. Its incidence is increasing, especially in regions where chronic hepatitis B virus (HBV) infection is endemic, which remains a major cause of the disease and significantly affects treatment outcomes.1,2 The therapeutic landscape for advanced HCC has been transformed by the introduction of molecular targeted therapies and immune checkpoint inhibitors (ICIs). The current standard first-line therapy for unresectable HCC has shifted toward the combination of atezolizumab (anti–PD-L1) and bevacizumab (anti–VEGF), supported by the landmark IMbrave150 trial, which demonstrated superior survival compared with sorafenib.3 Alternative first-line options include dual ICI regimens (eg, tremelimumab plus durvalumab) or tyrosine kinase inhibitor (TKI)-based combinations.4,5

    Despite these advances, a substantial proportion of patients exhibit primary resistance or ultimately develop progressive disease. Effective second-line therapies exist, particularly for patients who progress on or are intolerant to first-line anti-VEGF/ICI combinations. Regorafenib, cabozantinib, and ramucirumab (specifically for patients with baseline AFP ≥400 ng/mL) have demonstrated survival benefits in this setting.6,7 However, therapeutic options become increasingly limited and less effective beyond the second line, representing a critical unmet need in HCC management. The molecular heterogeneity of HCC, together with acquired resistance mechanisms, makes it particularly challenging to maintain disease control in the later stages.8

    Preclinical studies and emerging clinical evidence suggest that combining ICIs with either VEGF blockade or multi-target TKIs may provide synergistic therapeutic benefits.9–11 VEGF blockade can normalize tumor vasculature, potentially enhancing T-cell infiltration and improving the efficacy of ICIs, whereas TKIs exert broad anti-angiogenic and anti-proliferative effects by targeting multiple kinase pathways involved in HCC pathogenesis.12,13 While triplet combinations are being actively explored in first-line trials (eg, COSMIC-312), data on their use as later-line salvage therapy, particularly after progression on multiple prior lines including ICIs and TKIs, remain sparse and primarily confined to retrospective reports or small series.14,15 This lack of robust evidence creates significant uncertainty for clinicians managing heavily pretreated patients with preserved performance status.

    This case report describes a patient with advanced HBV-related HCC who showed rapid progression after initial transarterial chemoembolization (TACE) and subsequent systemic therapies, including bevacizumab/sintilimab and lenvatinib monotherapy. Faced with limited options and rising AFP, a salvage triplet regimen combining bevacizumab, sintilimab, and lenvatinib was initiated, resulting in a remarkable 10-month period of disease stabilization with manageable toxicity. This case provides valuable real-world evidence on the potential efficacy and tolerability of aggressive salvage triplet therapy in the challenging setting of multiply pretreated advanced HCC, underscoring the need for further prospective evaluation.

    Case Presentation

    A 67-year-old male presented to our hospital on March 6, 2023, after the incidental discovery of a hepatic mass during a routine physical examination three days earlier. Initial evaluation at an external facility included a PET-CT scan (February 24, 2023), which revealed a 3.1-cm FDG-avid lesion in segment 8 of the right hepatic lobe, suggestive of HCC. Additional findings included multiple FDG-avid subcapsular nodules in the right inferior hepatic lobe (suspicious for small HCC), numerous intrahepatic short-T1-signal nodules with abnormal FDG metabolism (suggestive of intrahepatic metastases), and enlarged FDG-avid lymph nodes in the hepatic hilum, abdomen, and retroperitoneum (indicative of metastatic involvement). Additional imaging findings included cirrhosis, splenomegaly, and ascites. Serum AFP was markedly elevated at 1028.84 ng/mL. The patient had a 30-year history of chronic HBV infection without prior antiviral therapy, with an admission HBV-DNA level of 10³ IU/mL. He denied any family history of malignancy, significant comorbidities, smoking, or alcohol use. Physical examination confirmed abdominal distension and shifting dullness. His performance status was ECOG 1. Based on his history of chronic HBV infection, elevated AFP, and corroborative imaging findings, a clinical diagnosis of primary HCC was established. Staging identified cT2N1M0 disease (Stage IVA), with Child-Pugh B cirrhosis (score 8; Table 1) and BCLC stage B disease. Liver biopsy was deferred.

    Table 1 Child-Pugh Score and Subcomponents for the Patient

    Initial management began on March 8, 2023, with TACE involving intra-arterial infusion of an epirubicin (30 mg)–lipiodol emulsion (4 mL), followed by embolization with polyvinyl alcohol particles. Concurrently, entecavir antiviral therapy was initiated. Systemic therapy began on March 28, 2023, with the combination of bevacizumab (400 mg IV on day 1) and sintilimab (200 mg IV on day 1) administered every 21 days. The treatment was well-tolerated initially, with no significant adverse events recorded. However, after three cycles, restaging abdominal CT on June 13, 2023, showed progressive disease (iuPD per iRECIST criteria; Figure 1A). An additional cycle of bevacizumab plus sintilimab was administered, but subsequent CT on July 20, 2023, confirmed further hepatic progression (icPD, Figure 1B). Therapy was switched to lenvatinib (8 mg orally once daily). Disease progression persisted after two months, as confirmed by abdominal CT on September 13, 2023 (Figure 1C), prompting a second TACE on September 18, 2023, using the same epirubicin–lipiodol/PVA regimen.

    Figure 1 CT variations of intrahepatic lesions during treatment (red arrowheads). (A) June 2023. (B) July 2023. (C) September 2023. (D and E) November 2023 and January 2024. (F and G), March and May 2024. (H), June 2024. (I), July 2024.

    Faced with rapid tumor progression and continuously rising AFP levels (Figure 2), alongside the prohibitive cost and low expected response rate of later-line options like ramucirumab, a multidisciplinary team (MDT) discussion was convened. Considering the patient’s preserved performance status (ECOG PS 1) and relatively good general condition, the decision was made, in consultation with the patient and family, to pursue an aggressive salvage triplet regimen. This regimen consisted of bevacizumab (400 mg IV on day 1) and sintilimab (200 mg IV on day 1) every 21 days, plus lenvatinib (8 mg orally daily). Following initiation of this combination therapy, a dramatic decline in AFP levels was observed (Figure 2).

    Figure 2 Serum AFP levels (normal <20 ng/mL) from March 2023 to July 2024.

    The patient remained on this bevacizumab/sintilimab/lenvatinib regimen regularly until July 2024. Serial abdominal CT scans during this period demonstrated sustained disease stabilization (Figures 1D–H). Treatment-related adverse events were limited to grade 1 fatigue and grade 1 hemoptysis. Disease progression was eventually documented on abdominal CT in July 2024 (Figure 1I). Subsequent therapy with regorafenib (120 mg orally daily) failed to control the disease, as evidenced by persistently rising AFP levels. Regorafenib was discontinued after two weeks, and the patient transitioned to best supportive care. He succumbed to multiorgan failure two weeks later. Notably, the systemic therapy that provided the greatest clinical benefit was the novel bevacizumab/sintilimab/lenvatinib triplet, which achieved 10 months of disease control. The overall treatment timeline is summarized in Figure 3.

    Figure 3 The overview of the approaches to diagnosis and treatment regimens for each regimen.

    Discussion

    This case report describes the successful application of an aggressive salvage triplet regimen—bevacizumab, sintilimab, and lenvatinib—in a patient with advanced HBV-related HCC who experienced rapid disease progression despite multiple prior lines of therapy, including TACE, bevacizumab/sintilimab, and lenvatinib monotherapy. Achieving 10 months of sustained disease stabilization with manageable toxicity (grade 1 fatigue and hemoptysis only) in this challenging clinical scenario provides valuable insights into the potential of later-line combination strategies and warrants further consideration.

    The patient’s disease course underscores the aggressive nature of HBV-related HCC and the limitations of sequential monotherapies or standard dual combinations in the post–first-line setting. Initial progression on the bevacizumab/sintilimab regimen, which mimics the standard-of-care atezolizumab/bevacizumab backbone,3 and subsequent failure of lenvatinib monotherapy,5 highlights the development of resistance mechanisms commonly encountered in advanced HCC.8 The molecular heterogeneity of HCC and the evolution of resistance pathways under therapeutic pressure pose significant challenges to sustaining disease control, particularly in later lines.8,16 Faced with rapidly rising AFP levels and diminishing options, the multidisciplinary team’s decision to combine all three agents previously used separately represented a rational, albeit unconventional, salvage approach.

    The observed efficacy of the bevacizumab/sintilimab/lenvatinib triplet can be interpreted through the lens of synergistic mechanisms targeting multiple facets of HCC biology. Preclinically, VEGF inhibition by bevacizumab promotes vascular normalization, which may reduce immunosuppression and enhance T-cell infiltration into the tumor microenvironment, thereby potentially overcoming resistance to ICIs such as sintilimab (anti–PD-1).12,17 Allen et al demonstrated that combined anti-VEGF and anti-PD-L1 therapy could stimulate tumor immunity through high endothelial venule (HEV) formation, facilitating lymphocyte access.13 Concurrently, the multi-kinase inhibitor lenvatinib provides potent anti-angiogenic effects (targeting VEGFR1-3, FGFR1-4, PDGFRα, RET, KIT) and direct anti-tumor activity,5,18 potentially addressing escape pathways that single-agent TKIs or VEGF blockade alone may not overcome. The significant and rapid decline in AFP observed after initiation of the triplet therapy strongly suggests a profound biological impact on the tumor.

    Our findings resonate with emerging, albeit limited, clinical data exploring triplet regimens in HCC. While large Phase 3 trials like COSMIC-312 (cabozantinib + atezolizumab vs sorafenib) focused on the first-line setting and yielded complex results,14 they demonstrate the feasibility of combining TKIs and ICIs. The rationale for adding VEGF inhibition to this backbone is supported by the IMbrave150 success3 and preclinical synergy.12,13,17 However, robust data on triplet combinations specifically in the salvage setting, especially after progression on prior ICI and TKI therapies, are exceedingly scarce. Most evidence comes from retrospective series or small prospective studies reporting variable outcomes.19,20 A retrospective analysis by Scheiner et al suggested potential benefit from ICI rechallenge combined with TKIs and/or locoregional therapies in selected patients.19 Our case adds to this emerging body of evidence by documenting a significant and durable response (10-month PFS) to a specific triplet combination in a heavily pretreated patient who had clearly progressed on both an ICI/anti-VEGF combination and TKI monotherapy.

    The manageable toxicity profile observed (grade 1 fatigue, grade 1 hemoptysis) is a crucial aspect of this case. Combining agents with overlapping toxicities, particularly the risks of hypertension, proteinuria, bleeding, and immune-related adverse events (irAEs) associated with bevacizumab, lenvatinib, and ICIs, raises significant safety concerns.3,5,21 The absence of high-grade toxicities in this patient suggests that careful patient selection (good ECOG PS 1, adequate organ function, absence of significant comorbidities or history of severe irAEs) and vigilant monitoring may allow for the safe administration of such aggressive regimens. This aligns with the safety profile reported in trials exploring doublet ICI/TKI combinations14,22 and suggests that adding a third agent may not inevitably lead to unacceptable toxicity in well-managed settings. However, larger cohorts are needed to fully define the safety profile of salvage triplets.

    Several limitations inherent to a single case report must be acknowledged. The response could potentially reflect delayed effects of prior therapies; however, the temporal association with triplet initiation and the immediate AFP decline argue against this explanation. The absence of molecular profiling limits our ability to identify specific biomarkers predictive of response to this regimen. Furthermore, the generalizability of this experience is uncertain. The prohibitive cost of such combinations and the lack of predictive biomarkers pose significant challenges for widespread adoption. The subsequent rapid progression after discontinuing the triplet, together with the failure of regorafenib, underscores the relentless nature of advanced HCC and the need for a better understanding of resistance mechanisms to combination therapies.8,16

    This case highlights a critical unmet need: the lack of established, effective options for patients with advanced HCC who progress on standard first-line and second-line therapies.8,16 While guidelines offer options like regorafenib (if first-line was sorafenib), cabozantinib, or ramucirumab (for AFP-high) in the second line,6,7,23 evidence for third-line and beyond is weak. Our experience suggests that carefully selected patients with preserved performance status may derive substantial benefit from aggressive salvage triplet regimens combining mechanisms previously used separately. This strategy warrants further investigation in prospective clinical trials or well-designed retrospective cohorts. Future research should focus on identifying biomarkers to select patients most likely to benefit from such intensive approaches and on optimizing sequencing and combination strategies to maximize efficacy while minimizing toxicity and cost.

    Ethics Statement

    This study was approved by the Ethics Committee of Quzhou People’s Hospital. The approval explicitly covered the publication of the case details. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

    Acknowledgments

    The authors thank the patient for his participation and agreement to publication of the report. Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.

    Funding

    The study was supported by Instructional Project of Quzhou (2020057, 2021005), Science and Technology Key Project of Quzhou (2022K48, 2022K138), “New 115” Talent Project of Quzhou, and “258” Talent Project of Quzhou.

    Disclosure

    The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

    References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660

    2. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y

    3. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745

    4. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070. doi:10.1056/EVIDoa2100070

    5. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1

    6. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9

    7. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-9

    8. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3

    9. Wang K, Liu C, Song X, Zhao N, Zheng X. Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma. Front Immunol. 2025;16:1594935. doi:10.3389/fimmu.2025.1594935

    10. Vitiello F, Tada T, Suda G, et al. Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): a real-world population. Semin Oncol. 2025;52(4):152348. doi:10.1016/j.seminoncol.2025.152348

    11. de Castro T, Welland S, Jochheim L, et al. Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort. Hepatol Commun. 2024;8(11). doi:10.1097/HC9.0000000000000562

    12. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29

    13. Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9(385). doi:10.1126/scitranslmed.aak9679

    14. Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. doi:10.1016/S1470-2045(22)00326-6

    15. Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117–127. doi:10.1200/JCO.22.00392

    16. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2

    17. Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195–203. doi:10.1038/nri.2017.145

    18. Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747. doi:10.1155/2014/638747

    19. Scheiner B, Roessler D, Phen S, et al. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep. 2023;5(1):100620. doi:10.1016/j.jhepr.2022.100620

    20. Xie F, Chen B, Yang X, et al. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma. Front Immunol. 2022;13:1052937. doi:10.3389/fimmu.2022.1052937

    21. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217–1238. doi:10.1016/j.annonc.2022.10.001

    22. Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399–1410. doi:10.1016/S1470-2045(23)00469-2

    23. Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991–1001. doi:10.1016/S1470-2045(21)00151-0

    Continue Reading

  • University of Sydney partners with Siemens Healthineers on $9 M MRI research capability

    University of Sydney partners with Siemens Healthineers on $9 M MRI research capability

    University of Sydney partners with Siemens Healthineers on $9 M MRI research capability

    September 13, 2025 | Saturday | News

    To unlock unprecedented medical imaging capabilities for researchers, clinicians and industry

    Australia’s University of Sydney has unveiled a $9 million partnership with Siemens Healthineers centred on the opening of the state’s most advanced magnetic resonance imaging (MRI) scanner.

    Developed through a strategic research partnership between the University and Siemens Healthineers, the Cima.X 3T MRI Clinical Research Facility delivers imaging capabilities not previously available in NSW, strengthening the state’s capacity for advanced medical research and clinical translation.

    Chancellor David Thodey AO said the MRI scanner in the new Sydney Imaging facility is the most powerful clinically approved whole-body MRI scanner in the world.

    The new Cima.X MRI scanner forms part of an integrated imaging suite located alongside the University’s Hybrid Theatre, a research-dedicated surgical operating theatre equipped with advanced imaging technologies at the Charles Perkins Centre.

    The new 3T MRI scanner features powerful gradient technology, enabling faster, sharper, and more detailed imaging. This allows researchers to map the brain in fine detail, detect disease markers earlier, and study heart and musculoskeletal conditions with unprecedented clarity.

    Researchers will be able to use the facility for studies ranging from mapping brain pathways in dementia and multiple sclerosis, to testing new therapies for depression and anxiety, to improving diagnosis of heart disease and sports injuries.

    It will also support cancer research by enabling earlier tumour detection and real-time tracking of treatment response, alongside the development of new surgical tools and robotic systems guided by MRI.


    Continue Reading

  • Super Mario Galaxy 1, 2 arrive on Nintendo Switch alongside new movie

    Super Mario Galaxy 1, 2 arrive on Nintendo Switch alongside new movie



    Super Mario Galaxy 1, 2 arrive on Nintendo Switch alongside new movie

    Nintendo has officially announced that both Super Mario Galaxy and its sequel, Super Mario Galaxy 2, are coming to the Nintendo Switch. The announcement was made during a recent Nintendo Direct presentation.

    This is a big news for fans because Super Mario Galaxy 2 was not included in the previous Super Mario 3D All-Stars collection, which featured the first Galaxy game. Now, for the first time, both of these classic Wii games will be available on the same modern console.

    The game will be released on October 2, 2025.

    The release of these games is a part of larger celebration for Mario’s 40th anniversary
    The release of these games is a part of larger celebration for Mario’s 40th anniversary

    The two games will be sold together as a physical collection for a price of $69.99. Users can also buy the games digitally from the Nintendo eShop. They will be available individually for about $39.99 each.

    The new version will have some improvements, including: Better graphics, updated control options, a new assist mode, an in-game music player, and new pages added to Rosalina’s storybook.

    The release of these games is a part of larger celebration for Mario’s 40th anniversary. It’s also happening alongside the announcement of a new movie. The sequel to the hit The Super Mario Bros. Movie will be called “The Super Mario Galaxy Movie” and is set to be released in April 2026.

    The announcement was made during a recent Nintendo Direct presentation
    The announcement was made during a recent Nintendo Direct presentation

    According to IGN, “Nintendo has announced the beloved Super Mario Galaxy and Super Mario Galaxy 2 are headed to Nintendo Switch and Switch 2, as part of Super Mario’s 40th anniversary celebration.”

    The new storybook pages in the game are said to connect to the film, giving fans a sneak peek into the lore.

    To celebrate, Nintendo is also releasing new products. Two new Amiibo figures are coming out, featuring “Mario and Luma” and “Rosalina and Lumas.” They will be available on April 2, 2026, which is close to the movie’s release.

    A hardcover version of Rosalina’s storybook is also planned

    Can users play Super Mario Galaxy on the Switch?

    Yes, Super Mario Galaxy is already playable on Nintendo Switch via the limited-time digital release of Super Mario 3D All-Stars.

    Continue Reading

  • Anticipations and Requirements of Individuals with Long-term Health Co

    Anticipations and Requirements of Individuals with Long-term Health Co

    Introduction

    Long-term health conditions, including hypertension, diabetes, cardiovascular diseases, and respiratory ailments, are recognized as principal factors contributing to global mortality and morbidity, creating increasing strain on healthcare systems, and resulting in financial challenges owing to ongoing treatment requirements. This challenge is particularly evident in nations such as Saudi Arabia, where the prevalence of chronic conditions continues to rise, presenting significant challenges to the healthcare infrastructure.1,2

    As these conditions become increasingly common, healthcare systems are placing greater emphasis on enabling patients to play an active role in managing their conditions. Healthcare professionals view self-management as a crucial element of chronic care. Individuals with long-term health conditions must make daily decisions in order to manage their health. Self-management necessitates that patients actively handle their treatment regimens, symptoms, psychosocial and physical consequences, and lifestyle modifications.3

    However, achieving optimal self-management behavior presents significant challenges and requires considerable patient effort. Previous studies have demonstrated that individuals with chronic conditions encounter numerous obstacles to active self-management,4,5 including difficulties with weight control, maintenance of regular exercise routines, depression, pain, fatigue, poor communication with doctors, and insufficient family support.

    The digital health (eHealth) technologies that individuals with chronic conditions can employ in their homes are anticipated to play a significant role in supporting self-management. eHealth encompasses a broad spectrum of technological innovations in the health care sector. It is described as “an emerging field at the intersection of medical informatics, public health, and business, referring to health services and information delivered or enhanced through the internet and related technologies.6

    Various eHealth technologies provide support for people with chronic self-management. For instance, electronic coaching and monitoring apps assist with dietary choices, exercise routines, weight management by offering personalized feedback and motivation as well as artificial intelligence (AI)-based tools.7–10 These tools also help individuals manage their depression and anxiety. Furthermore, electronic communication tools enable effective interaction between patients and healthcare professionals.11–13 Home monitoring systems for chronic conditions generate accurate data, promote patients, affect their behaviors and attitudes, and enhance medical outcomes.14 Furthermore, AI-powered tools—such as intelligent decision support systems and Chabot’s—provide customized recommendations depending on personal health data and actively control their health issues.15 Recent reviews indicate that digital health shows promise in supporting the self-management of chronic conditions.10,11,16,17

    Nevertheless, eHealth often fails to be successfully integrated into daily care routines.18,19 One primary reason for this is non-adoption by individuals. The reported justifications for non-use and withdrawal include a lack of further advantages from digital health solutions, the belief that conventional healthcare is adequate,18,20–22 technical challenges with the equipment, and the association of digital health with increased dependency and poor health status.22

    An additional challenge is that eHealth frequently lacks personalization for individual patients or relevant cultures.19,21,23 Before implementing new digital health technologies, it is essential to consider how patients currently control their condition and adapt their lifestyles according to their chronic illness. Research has established that self-management activities are partially condition-specific and general.24 Individuals with neurological or diabetes conditions perceived more daily self-management activities than those with other long-term diseases such as chronic obstructive pulmonary disease (COPD) or cardiovascular disease. The perception of the compatibility between daily regimes and digital health solutions is crucial for successful adoption and utilization.19,21

    Before digital health can be effectively implemented, it is vital to include potential users in order to understand their requirements and needs. User-centered design is commonly employed to involve patients in digital health design and development.25,26 Most studies have utilized a user-centered design to enhance the usability and functionality of digital health technology. However, little attention has been devoted to the preliminary stages of development and design.27 A fundamental question emerges: Which components of self-management do individuals with long-term conditions require further support? If they require help, are they genuinely able to utilize digital health solutions?

    Although addressing patients’ needs and preferences could positively influence the acceptance and successful implementation of digital health in self-management,20,22 potential users have rarely been consulted and involved during development.28,29

    Moreover, while digital health is receiving increasing prioritization and promotion globally, there has been limited research exploring chronic patients’ views, expectations, and needs towards these technologies.13,25 Although eHealth is increasingly used in chronic disease management, there remains a lack of qualitative research that captures patients lived experiences, condition-specific needs, and digital readiness across a range of chronic illnesses. Most existing studies focus on an individual condition or general attitudes, rather than exploring comparisons in cross-condition and nuanced patient perspectives, or they often uses quantitative or mixed methods evaluating clinical outcomes or effectiveness.30

    While eHealth is increasingly promoted for chronic disease management, Still missing is qualitative research spanning several chronic diseases that reflects patients’ lived experiences, condition-specific requirements, and digital readiness.21 Rather than investigating cross-condition comparisons and complex patient viewpoints, most current investigations concentrate on a single condition or general attitudes.15 Additionally, although some qualitative work has begun to examine digital engagement among people with specific conditions like COPD or diabetes, these studies often highlight persistent barriers such as low digital literacy and lack of trust in digital tools without highlighting the differences between various chronic conditions.15 This disparity points to a pressing need for more inclusive, patient-informed studies that take into account different chronic illness experiences in the creation of eHealth solutions—including digital tracking tools, developing artificial intelligence technologies, and related innovations—as well as patients’ readiness to utilize them, so offering a thorough knowledge over a broader spectrum of common chronic diseases.

    This gap is more evident in the Saudi context or wider gulf region, where recent investigations have evaluated potential users from the general population or individuals with specific chronic conditions (such as diabetes) regarding digital health in managing their particular chronic condition, primarily through closed-ended questionnaires, without examining patients’ needs and requirements for support in self-managing their conditions or highlighting the differences between various chronic conditions.31–37

    Therefore, it is crucial to address this gap by examining this emerging topic to explore the expectations, viewpoints, and requirements of individuals living with long-term health conditions regarding areas of self-management where they desire further support and their attitudes towards eHealth for self-management.

    The primary aim of this investigation was to explore the opinions, expectations, and needs of individuals with long-term health conditions, and examine possible variations regarding areas of self-management where they desire further support, and their views towards digital health for self-management. Additionally, this study aimed to understand individuals’ willingness to use digital health technologies. To examine possible variations and differences among patient groups, individuals with 1) diabetes, 2) hypertension, 3) COPD and 4) cardiovascular conditions were included. These patient groups were selected because they represent major chronic condition types worldwide38 and within Saudi Arabia,1,2 and these groups may find eHealth to be useful for self-management.

    This investigation provides novel insights into how digital health can be tailored to address the unique challenges faced by patients with hypertension, COPD, diabetes, or cardiovascular diseases within this cultural context. It also contributes to the limited research on chronic condition management through digital health in Saudi Arabia, providing a more comprehensive understanding of patient-centered digital health interventions in this context.

    Materials and Methods

    Recruitment and Design

    An exploratory qualitative study was conducted to understand the expectations, viewpoints, and requirements of individuals needing support with the self-management of long-term health conditions, and their views towards digital health for self-management purposes. This was accomplished by focus groups of patients with chronic conditions. The informed consent was obtained from the study participants prior to study commencement.

    Participants

    This qualitative investigation was conducted in Riyadh, Saudi Arabia, which is the capital city of Saudi Arabia, and its largest population center. Convenience sampling was employed to recruit patients (n = 37) at the two primary care centers using flyers. Ethical approval for this study was obtained from the ethics committee of the Saudi Ministry of Health in Riyadh, Saudi Arabia (approval number 21–518E).

    The inclusion criteria required participants to be over 18 years old and diagnosed with one of the following chronic illnesses: cardiovascular disease, diabetes, hypertension, or COPD. The exclusion criteria included cognitive impairment, severe psychiatric illness, or insufficient Arabic language proficiency, leading to an inability to comprehend the research information.

    Interested individuals received an information letter, then completed a consent form, and a questionnaire. The questionnaire gathered background information, including age, type of chronic condition, experience of using care technology (such as searching for information about their condition online, utilizing a remote coach, or utilizing a self-tracking system), and level of difficulty they experienced in using care technology.21

    The objective was to arrange two focus-group discussions for each condition. Focus groups were scheduled when a minimum of five to six individuals with similar chronic illnesses agreed to participate.

    A researcher (TA) asked patients to arrange suitable dates and times for the focus groups. The focus groups were conducted in the primary care center where the participants were recruited.

    Procedure

    The focus groups were facilitated by the TA and the assistant moderator (research assistant).

    Following an introduction regarding the aim and procedure, the following themes were explored: 1) the influence of the chronic condition on participants’ routines; 2) their views, requirements, and experience regarding self-management; and 3) their expectations, perceptions, and requirements regarding, and readiness to utilize, digital health for self-management support.

    Concerning the final theme, three distinct types of digital health applications were discussed: 1) self-tracking tools enabling individuals to track their health status, receive reminders, and share these with their healthcare professionals online; 2) remote coaches offering advice and information about conditions or lifestyles; and 3) online communication apps, such as phone or video consultation.

    During the discussion, participants were initially asked about their experience of using technologies or the internet for health purposes and their awareness of other digital health technologies. The various eHealth technologies mentioned by the participants are discussed below. The moderator introduced additional possibilities to ensure that the three types of digital health technology received similar discussion time between each focus group. The moderator’s role involved briefly introducing themes, encouraging participants to share their thoughts, and asking follow-up questions to clarify their opinions. Each focus group lasted approximately 60–90 minutes and was audio-recorded; the assistant moderator documented the written field notes.

    Data Analysis

    The focus group interviews were conducted in Arabic and transcribed word for word, and the transcripts were verified against audio recordings. Initially, the researchers independently analyzed the transcripts from each condition group (diabetes, COPD, hypertension, and cardiovascular disease). A content analysis method39 was employed to code the data because of the exploratory nature of the focus-group structure. The researchers verified the agreement between the variation codes of the initial four transcripts to ensure coding consistency. The primary researcher then applied this coding framework to the remaining four focus-group transcripts. Emerging codes were then incorporated if required. Subsequently, both researchers grouped the codes and consented to the themes and sub-themes of the coding framework, and any discrepancies were resolved by consensus. NVivo version 10 was used to code the transcripts. To ensure the integrity of the research data, coding was conducted in Arabic. Quotations reported within the results were translated first into English and then back-translated into Arabic to ensure the accuracy and trustworthiness of the translated data.

    Results

    Participant Characteristics

    Forty-six participants participated in this study, with an average age of 63.48 years (range, 44–82 years), as shown in Table 1. Of these, 55.3% were male. Two focus groups were created for each condition: hypertension (n = 6 and n = 6), diabetes (n = 7 and n = 6), COPD (n = 6 and n = 5), and cardiovascular conditions (n = 5 and n = 5).

    Table 1 Participants Characteristics

    Participants with COPD reported visiting their doctors once to twice a year. The majority had early to mid-stage COPD, with one patient experiencing COPD GOLD (Global Initiative on Obstructive Lung Disease) stage IV, resulting in pulmonologist consultations five times per year. Physiotherapy treatment had been received by three participants. All participants were on oral medication once or twice daily (eg, tablets and/or inhalers). Phone consultations had been experienced by only one participant; the other participants had never used eHealth technologies.

    Patients with diabetes visited their doctors between two and four times annually. Nine participants took only oral medications and four used insulin injections. Four participants had experience with chat communication with healthcare professionals. One patient used a diabetes monitor app to record and track blood glucose values and remind them to take medication. Another participant had previously utilized a diabetes health coach where he could input his blood glucose measurements to receive recommendations.

    Patients with hypertension visited their doctors between two and four times annually. All 12 participants only took oral medications. Two participants had experience in chatting with healthcare professionals. One patient used a hypertension monitor app to record and track blood pressure values and remind them to take medication. Another patient with hypertension reported that she had used a food diary.

    Patients with cardiovascular conditions visited their doctors between two and three times annually. Two patients visited a cardiologist annually. Five patients reported cholesterol levels and high blood pressure. Three patients reported having either a stent in place or having undergone angioplasty. All the participants used oral medications. One patient had experience of phone consultation with a healthcare professional.

    Themes

    Analysis of the study focus groups resulted in three main themes: views, needs, and expectations toward self-management; requirements and experience of using eHealth services; and factors affecting eHealth, as shown in Table 2.

    Table 2 Overview of the Study Findings (Theme and Sub-Themes)

    Themes Identified

    Views, Needs, and Expectations Toward Self-Management
    Knowledge and Awareness

    Most participants, excluding those with COPD, had sufficient information about their condition. However, some patients with hypertension and diabetes had knowledge gaps regarding the condition risks and their impact on self-management. Patients with COPD lacked fundamental information regarding their condition and management.

    Participants reported receiving information primarily from doctors, brochures, and the internet. However, some expressed concerns regarding online information reliability and noted that detailed medical information occasionally caused unnecessary anxiety.

    I had some information about the diseases; nowadays you can get information from everywhere; discussing with doctor, nurse or even my relatives, available broachers and even the internet, but sometimes when I read information on the internet I get shocked whether the information is medically correct or not Hypertension

    Being aware of the disease risks may help to be active in managing diabetes more; trying to eat more healthy food, having healthy lifestyle …etc. to avoid any future consequences Diabetes

    Adherence and Medication Management

    Different patterns have emerged for medication management across conditions. Most participants described medication use as a daily routine, although many reported difficulties with initial adherence. Patients with diabetes, who regularly monitored their blood glucose levels, appeared to be more active in medication management, adjusting doses as required.

    Participants with mild COPD and hypertension reported ongoing challenges with medication adherence, frequently due to a perceived lack of effect or absence of symptoms. A small number of patients discontinued their medication without consulting healthcare providers. Patients with cardiovascular disease generally demonstrate strong medication adherence, motivated by an understanding of the serious implications of non-compliance.

    Various medication-management strategies have been proposed. Some utilized pillboxes, while others employed technology, such as mobile phone alarms or medication reminder applications. One participant living with diabetes had previously used a diabetes coach in which he could enter his blood glaucous readings, where he could receive recommendations. Although he reported that this app might be beneficial for those with variable blood glucose values, he no longer used it, as it was not working well.

    I attempted to use a mobile phone alarm to remind me to take the medication, it proved very helpful Cardiovascular

    I employed a beneficial application recommended by my friend where I could establish a reminder not only for medication but also for measuring blood glucose and also I can share the data to receive an advice whether I increase the medication does? But Diabetes

    Monitoring and Managing Related Symptoms

    Requirements and expectations regarding symptom management varied considerably among patient groups.

    Patients with COPD express diverse views on home-based oxygen saturation and lung function monitoring. Some valued home monitoring tools for the early detection of worsening symptoms and the prevention of complications. They demonstrated positive attitudes towards healthcare professionals with remote access to their data for timely intervention and medication adjustments.

    Monitoring my lung function individually at home is really helpful in checking my health and catching any problem early COPD

    If my data available and my doctor can see online, he can let me know in case I need a check-up. COPD

    One COPD sufferer said he looked for an Arabic mobile app connected to COPD in app stores but came up empty.

    I looked for a COPD app in Arabic but found none. While there are many in English, I don’t know which one is the most relevant or appropriate for me. COPD

    Another participant recounted utilizing an AI-based tool (ChatGPT) to track their respiration levels. While some users welcomed the individualized insights, others expressed worries about the tool’s reliability.

    I entered my breathing level into ChatGPT, and it gave genuine comments. I was surprised by how it provided me tailored insights.actual comments about my situation COPD

    We’re still a bit afraid it might not be accurate all the time—it’s helpful, but it’s not a doctor. COPD

    This highlights the growing potential of AI applications beyond simple tracking. While many patients traditionally rely on monitoring tools, AI systems like ChatGPT are now capable of analyzing patient data, offering real-time feedback, and providing actionable recommendations. Such tools can assist in recognizing early signs of deterioration, giving patients confidence in their ability to manage COPD symptoms independently while fostering communication with their healthcare providers.

    Patients with diabetes and hypertension reported that doctors encouraged regular monitoring of their blood glucose and blood pressure. Most studies have attempted frequent measurements, either daily or weekly, or based on condition stability. Only a small number of patients measured their blood glucose and blood pressure when experiencing unwellness, such as fatigue, and then took medications based on these readings. Some patients with diabetes maintained their paper records during consultation visits. Some patients with hypertension and diabetes expressed uncertainty regarding the appropriate responses to abnormal measurements.

    I monitor my blood sugar frequently and wrote it in a paper, as doctor advised me, to take it in my appointment Diabetes

    Monitoring my blood pressure data assists me in keeping everything on track, but If I see my blood pressor abnormal I do not know exactly what I should do Hypertension

    Two patients (one each with diabetes and hypertension) reported using applications for recording measurements and appreciating features, such as graphical and tabular data presentation. Some patients with hypertension have suggested enhancing applications with explanatory text along with color-coded feedback for measurement deviations. Most patients with diabetes and hypertension suggest that the option to automatically send and share blood measurements to the healthcare professional would be helpful, as the care team then has real-time available data and could respond to it if that data deviates from the norm. They also reported potential advantages of tracking and sharing blood data values with healthcare professionals. Though some users appreciated the tracking capabilities in their monitoring apps for tracking their condition and spotting trends, others pointed out that the new AI-based apps might offer more advantages including real-time pattern detection, early alerts for glycaemic events like hypoglycemia or hyperglycemia, and personalized insulin dose recommendations. These features enabled them to more proactively and confidently control their condition. Some users also underlined that such tools can help doctors communicate with them, particularly when it is challenging to obtain an early appointment.

    The hypertension management app I use is very useful. I can track overview of my blood pressure data in table Hypertension

    The app would be more beneficial if it sending my measurement data automatically to the doctor and my daily data available to them, so he [the doctor] intervenes when something wrong Diabetes

    Though I occasionally require more thorough or tailored advice, such as when I should raise my dose or forecast when my blood pressure will worsen and what I should do, I have tracked my blood pressure using an app. Hypertension

    The AI app does so much more; I used to only monitor my blood sugar with an app. Even before I see it, it examines my data and alerts me if my sugar could go too high or low. It also advises me on actions to take, such as modifying my insulin or eating something. It’s like having a smart assistant cooperating with my doctor to help me control my diabetes. Diabetes

    Some individuals with cardiovascular disease felt that their condition had a minimal impact on their lives and reported few complaints due to minimal symptoms. Consequently, they might not perceive home monitoring as beneficial and may find routine health checks with doctors or nurses at health centers that are satisfactory for managing their condition. Two patients expressed that while home monitoring increased their awareness of their condition, it also generated more negative emotions.

    We don’t feel like patients at all because I rarely have any issues and it did not impact my everyday routine Cardiovascular

    Monitoring thing at home also would make me more conscious of my condition make me feeling uncomfortable Cardiovascular

    I don’t see any reason to monitor things at home. I am satisfied with my appointments with the doctors. Cardiovascular

    Healthy Lifestyle

    Participants across all groups acknowledged receiving warnings regarding lifestyle modifications upon diagnosis, although many admitted an initial lack of awareness about risks and consequences that deterred changes. They emphasized the role of healthcare professionals in raising awareness about lifestyle modifications to prevent complications.

    Smoking cessation was particularly discussed in the hypertension and COPD groups, with participants acknowledging difficulties despite understanding their health benefits. Exercise was discussed across all groups, with cardiovascular, diabetes, and hypertension patients noting its benefits, whereas COPD patients reported reduced activity due to breathlessness. Many expressed uncertainty regarding appropriate exercise types and durations, particularly in individuals with cardiovascular conditions and COPD, suggesting the need for medical guidance and tracking tools.

    I know being active help me to control my cholesterol and strength my heart muscle so I want to be active bur sometimes I said may be running is not suitable for you Cardiovascular

    There are some obstacles affecting doing exercise regularly including not knowing which most suitable exercise, hot weather, lack of motivation Hypertension

    Nutrition and diet were especially significant in patients with diabetes and hypertension, who noted immediate effects on blood glucose and pressure levels. One patient with hypertension mentioned that she used a food diary app, but this app was not specifically designed for Saudi people; therefore, she stopped using it. One patient with diabetes noted that although calorie-tracking applications exist, they are not tailored to specific chronic conditions. Diet management challenges include a lack of awareness of condition risks, social pressure, busy lifestyles, and forgetfulness. Another diabetic participant said that an AI-powered software provided a better tailored experience; the app adjusted to users’ daily habits and health behavior over time. Key lifestyle variables including particular meals, exercise, and even device faults could be found by it, therefore enabling the system to provide timely and customized feedback on his glaucous level. This degree of customization helped users feel more supported in their self-management initiatives, hence enabling them to make educated decisions and keep better control of their condition with more confidence and safety.

    Yes, I agree that a healthy diet helps manage my diabetes. For example, I noticed that when I eat sweet food, my blood sugar goes up” Diabetes

    I think a healthy lifestyle isn’t that important for my heart condition; medication is what really matters.” Cardiovascular

    We [patients with heart diseases] get information from our doctor, brochures.etc, but we may need more encouragement to live healthier, like reminders to exercise. Cardiovascular

    “Having the drive to actually make changes is what’s really important.” Cardiovascular

    “I had used a food diary app but I realized the app does not fit because it did not have the ingredients I used to eat” Hypertension

    “I read about an AI app it seems it learns about me over time—it knows my habits, like when I eat or exercise, and even spots if something’s wrong with my device. It gives me tips that fit my lifestyle, not just general advice. I feel like it helps me make better choices and stay safer every day.” Diabetess

    Cardiovascular patients generally view dietary changes as less critical than medication. Most participants seemed to have no interest in employing an online coach to encourage and motivate them to adopt a healthy lifestyle, such as an online coach assisting with quitting smoking. Intrinsic motivation to live a healthy life is generally considered important, with health information available from brochures, healthcare professionals, and the internet.

    Psychological Consequences

    All participants reported an initial shock and difficulty accepting their chronic condition. Patients with diabetes and COPD expressed anxiety regarding symptom management and uncertainty regarding appropriate responses. Patients with hypertension are worried about their asymptomatic condition, which leads to frequent monitoring. Cardiovascular patients were particularly worried about life expectancy implications and showed a higher tendency toward depression. Patients with COPD experience breathlessness, particularly frightening and stress.

    “At the beginning, I couldn’t believe I had this condition. I thought I was too young to get it and said it was because of eating high-calorie food, like too much sweet and rice. I wondered how my life would change.” Diabetes

    “In my diabetes, sometimes I feel dizzy or my BG is low, and I do not know exactly what I should do; do I eat sugar, do I rest, or do I need to take my medication?” Diabetes

    “As someone with heart disease, I feel like I will die soon, which makes me even sadder.” Cardiovascular

    “Getting breathless is really scary. I am stressed when I can’t breathe or when I cannot do deep breathing very well… it would be good if letting us know what is the right steps in how to breath well” COPD

    While many recognized the value of health monitoring applications, some noted that these tools could increase anxiety, particularly when tailored recommendations for managing readings are lacking.

    “I use apps based on what they do [their functions]. Some apps can make me more anxious by showing my BG as very low or high without giving specific helpful advice for managing my disease.” Diabetes

    Social Support

    Participants across groups valued support from friends and relatives, particularly those with similar conditions, finding comfort in shared experiences and advice. Some regularly sought assistance from their children for various health-related tasks. However, some preferred discussing health matters exclusively with health care professionals. Few participants noted using applications to connect with others sharing their condition, although the Arabic language options were limited.

    “Talking with others who have the same disease and discussing our struggles, experiences, and goals makes me feel comforted, understood, and less alone” COPD

    “I usually contact my son to help me when I feel my blood pressure is high, book an appointment, or even bring medication from the pharmacy.” Hypertension

    “I used an app to connect with others from different countries to discuss our difficulties, medications, and experiences. However, there is no app available for Arabic speakers. Diabetes

    Current and Expected Communication with Doctors

    Participants reported satisfactory regular access to doctors and the ability to arrange follow-up appointments through the Ministry of Health (MOH) application. However, patients with cardiovascular disease and COPD experience difficulties in accessing specialists between scheduled visits. They suggested that enhanced communication options such as online video consultations could better address their needs. Participants emphasized the importance of considering elderly individuals’ needs when designing these tools. Particularly for chronic disease management, some attendees recommended using technology developments—including artificial intelligence tools—to supplement the doctor’s function by providing tailored alerts, early warnings about symptom changes, and unambiguous, practical advice. Particularly for patients with chronic diseases, this would assist to close the gap between visits and guarantee prompt actions.

    “I can usually reach my doctor by booking appointments through the MOH app, but sometimes I can’t get a quick appoint ……. Online Chat or video consultations would be a big solution to help me get answers and discuss my needs sooner.” Cardiovascular

    “The app driven by artificial intelligence can interpret my health data. It offers recommendations on what to do next and early alerts when something might change—like my blood sugar, blood pressure, or even my respiration levels. Especially when getting an appointment is difficult, it’s like having a smart assistant working with my doctor to help me remain in charge of my health; I would feel more supported between appointments.” Diabetes

    Participants reported that regular apps mainly served as symptom trackers and required manual input, offering little real-time support or guidance. In contrast, AI-powered eHealth tools provided personalized alerts, early warnings about symptom changes, and actionable recommendations like when to use inhalers or perform breathing exercises. The addition of AI chatbots also offered emotional support and 24/7 assistance, helping users feel less alone. Overall, AI tools transformed COPD management from passive recording to active, intelligent self-care.

    Requirements and Experience of Usage eHealth Services

    Most participants began utilizing digital health tools such as telephone consultations during the COVID-19 pandemic. Initially, elderly individuals struggled and resisted using these tools. However, many gradually adapted and found certain digital health services, such as electronic prescriptions, helpful in managing their care. They expressed willingness to continue using these services after the pandemic for tasks, such as appointment booking.

    “During COVID-19, we had to use phone consultations because in-person visits weren’t possible. I found it easier and more useful than going in person” Hypertension

    “but dealing with technology can be challenging, so I ask my child for help with things like ordering medication and booking appointments.” COPD

    The majority across all groups recognized digital health’s potential in supporting self-management but emphasized that it should complement rather than replace in-person care. COPD and cardiovascular patients in particular note that certain conditions require physical examination that cannot be accomplished through video consultation alone.

    “I did not prefer to do all my consultation online, I think it is difficult if my disease can be examined remotely via video … there is still important to see doctors in person and discuss the condition with him/her.” Cardiovascular

    “ Electronic services are good for supporting regular hospital care and self-manage my disease but shouldn’t replace it. I still think seeing a doctor in person is important.” Diabetes

    Most patients suggested implementing digital health services, while allowing users’ choices for adoption. Some worried that making such tools optional might lead to resistance from those averse to change, given rapid technological development. A few patients with cardiovascular disease expressed concerns about the potential negative consequences of inconsistent tool usage.

    “Not all participants have the same interest to use technology so it would be great if patients have the choice if he can use it or not …… I am afraid if this tool is compulsory and I was not adhered with it what will happen for me.” Cardiovascular

    “To encourage patients to use it, we need to tell them about the short-term and long-term benefits and advantages.” Diabetes

    “I know some patients don’t like change and prefer their usual routines, so it’s important to support them in using technology and then help convince them of its benefits.” Hypertension

    “Giving patients choice and getting more advantages in using eHealth services will may increase it’s adoptions.” COPD

    Expected Benefits of Using eHealth

    The participants noted that the expected benefits depended on the specific services offered, such as improved appointment access, reduced waiting times, and easier specialist access. Patients with hypertension and diabetes anticipated the benefits of active self-management including daily reminders, monitoring support, and educational information. Patients with COPD suggest that these tools would be most beneficial if they enhance their disease understanding and coping strategies. Conversely, several diabetes and hypertension sufferers said that while normal eHealth tools are helpful, they are more passive than AI driven eHealth tools, such as apps. By providing, for example, glucose Trend Prediction and…

    “I used to simply record my blood sugar on a regular app, but that didn’t much enable me to grasp what was happening. It truly tells me when my levels might go high or low after switching to the AI-based app; it looks at my historical readings and recommends what I can do. For instance, it highlighted something I had never seen before: my blood sugar usually rises after lunch on weekdays. It feels like carrying a tiny doctor in my pocket.” Diabetes

    “Current electronic services make it easier to see doctors. For example, I can book an available appointment via the app and then meet the doctor right away, without long waits. I also receive a message letting me know when I can pick up my medications, so I don’t have to ask the pharmacist for re-prescription.” Diabetes

    “Access to my health information is easy through the app. It tells me if my blood pressure is normal and reminds me to take my medication.” Hypertension

    “Access to educational information is very easy through the app I downloaded. I can learn more about my conditions[COPD] and more.” COPD

    Factors Affecting eHealth Use

    Most participants emphasized the need for simple, clear navigation, and minimal required actions, particularly for those unfamiliar with technology. Elderly users often report difficulties with small text sizes, unclear layouts, and technical problems that sometimes require family assistance.

    “As we get older, we might find it hard to use, even if we can read and write. Sometimes, I need to ask my son for help to enter medication names and dose because the size is very tiny small to read or write.” Hypertension

    “Many things need to be considered to make the service easy to use, like font size, background color.etc.” Cardiovascular.

    “Easy navigation between screens is crucial to avoid confusion” Diabetes

    “I am not used to use technology so it is very important this tool to be easy to use” COPD

    Some participants discussed the importance of involving potential users in digital health service design in order to ensure alignment with their needs and preferences. Users with previous application experience preferred both manual and automatic data-entry options.

    “It’s important to think about what users need before setting up these services or tools. Ask them what they want the service to do, how it should work, and details like colors and design” Cardiovascular

    “I prefer the tool to include only the essential features and leave out the ones that aren’t needed.” Hypertension

    “Having both manual and automatic data entry options via linked devices to make the process easier., like in some apps I’ve used, makes the tool easier to use.” Diabetes

    Most patients expressed minimal concerns about privacy when using MOH services, although some high-profile individuals preferred the assurance of data security. Many reported being unaware of available services or proper usage methods, suggesting the need for awareness campaigns through various media channels. They recommended providing training (in person or online), written instructions, and technical support to overcome barriers to adoption.

    “I don’t mind sharing my information as long as it’s used to support my care” COPD

    “I’m not worried because the information entered is not sensitive.” Hypertension

    “I am very careful about sharing my health information because as you know I am well-known person. I never put my confidence on apps or websites because it may share with others” Diabetes

    “It’s helpful to let patients know about available services because we often only find out about them suddenly through receptionists or doctors.” Hypertension

    “if the digital services are promoted via different method via twitter or snapchat or on TV patients can become aware of it”. COPD

    “Training patients or giving them instructions on how to use the services will definitely help and encourage us to use them.” Diabetes

    “Providing 24-hour technical support can resolve any issues and make it easier for more people to use the service.” Cardiovascular

    The present research indicates a general willingness to engage with digital health, and shows support for new systems that utilize emergent technologies such as AI to improve the user experience. However, another key finding of this study is that attitudes towards eHealth varied across the four patient groups, suggesting that policy-makers may need to develop tailored solutions to suit different chronic conditions. The results also highlight the relative lack of eHealth self-management systems targeted at specific chronic conditions, and/or tailored to a Saudi context, eg food tracking apps tailored toward Saudi people and/or Arabic-language communication apps. This suggests that the creation or commissioning of new eHealth systems tailored toward these unique patient groups and/or to the Saudi population specifically should be key policy goals.

    Discussion

    This qualitative investigation revealed notable differences and similarities between patient groups regarding viewpoints, expectations, and requirements for self-management and digital health support. Generally, diabetes and hypertension patients recognized more viewpoints and potential advantages regarding self-management areas and showed the greatest willingness to utilize digital health, followed by COPD patients and then cardiovascular patients. All groups attempted to maintain health and reported similar general requirements for digital health, while identifying key usage factors. Participants emphasized that digital health adoption should be patient-driven rather than healthcare professional-mandated and should supplement rather than replace personal care.

    Although digital health adoption has been extensively researched, this study offers a fresh viewpoint by investigating the particular views of Saudi Arabia’s chronic condition patients in a location witnessing fast digital change in healthcare. The Saudi healthcare system is a public-sector body, which delivers treatment to the majority of chronic disease patients in the country.2,31,36 By investigating culturally specific obstacles and enablers affecting digital health self-management among patients of the Saudi healthcare system, the study offers valuable insights to inform national policy on eHealth and chronic disease, and which could also be useful to other nations with comparable healthcare systems. Furthermore, our results draw attention to specific patient issues, including trust in digital platforms, accessibility issues, or policy-related aspects, which have been underexplored in current research. This work is useful outside a local context since it offers a wider knowledge of how eHealth uptake is shaped by contextual elements by contrasting these findings with outside studies.

    The self-management techniques presented in this study were broadly aligned with those identified in previous studies.3,40 Generally, more viewpoints were discussed regarding medication management, educational information, symptom management, lifestyle, and communication than regarding social support and the management of psychological consequences. Participants attempted to adopt different self-management strategies and techniques to stay healthy, such as self-monitoring blood data, lung function, and exercise. However, they discussed less about managing the psychological effects inherent in living with a long-term health disease, although stress was identified as affecting the adoption of self-management strategies. This may reflect that self-management approaches primarily focus on behavioral and medical management, with less emphasis on helping patients manage the emotional effects of chronic diseases,21 despite stress and anxiety being common barriers to effective self-management. Moreover, the healthcare system and cultural differences may influence self-management approaches.33

    The variations among individuals with hypertension, diabetes, COPD, and cardiovascular conditions in terms of requirements, opinions, and expectations in relation to self-management and digital health may be related to variations in symptoms, treatment, and level of control among condition groups. Most individuals with diabetes and some participants with hypertension were already aware of the self-tracking apps for monitoring blood pressure and glucose levels. Additionally, these patients reported that adopting a healthy lifestyle and adherence to medication directly influenced their health. However, patients with hypertension often forget medications because they are asymptomatic. Some diabetics and hypertensive people also said they liked AI-powered tools since they understood the particular qualities such technology provide, including help in deciding the right medication dose and forecasting possible blood pressure or glucose level increases. Therefore, these patients might perceive their condition as more controllable through their behavior, potentially increasing interest in digital health for self-management if it supports measurement recording and activity tracking, and provides medication and exercise reminders—paired with artificial intelligence-based solutions, these might improve patient involvement with eHealth systems and assist long-term disease control.7,41

    In contrast, patients with cardiovascular disease reported few complaints and had a minimal impact on their daily life. Many perceived no need for digital health monitoring as regular health checks were sufficient, although they preferred tools to track and determine suitable exercises. Patients with COPD expressed more psychological and physical consequences, frequently mentioning declining health status and diminished life enjoyment, and wondering about future disease progression. This may indicate a sense of diminished control over their illness, requiring more support in knowledge enhancement and breathing technique instruction through active videos.42 A study in Netherland backs this up by showing that the sensation of having less control over their sickness could reduce the extra benefit of employing eHealth for self-management assistance.21 Furthermore, language obstacles and/or low eHealth knowledge made digital health solutions for COPD management less available to Arabic-speaking users. Research indicates that Arabic-speaking immigrants in Sweden struggle to use digital health technologies43 although Arabic is a widely-spoken language in the Middle East.37 This highlights the significance of recognizing local language and social traditions Apart from the eHealth tool dependability in the implementation of eHealth interventions among chronic illnesses, particularly COPD and hypertension.31,37,44,45

    Furthermore, while not the main emphasis of this research, certain individuals in this study showed curiosity about how artificial intelligence (AI) might assist chronic condition management, especially via applications like personalized recommendations, health monitoring, and early alerts, where is mentioned by Bijun Wang et al, 2023.30 This implies increasing patient awareness and willingness to digital instruments augmented by artificial intelligence.46 Though AI has promise in chronic condition self-management,7,15,41 a recent review found that many studies remain in the early stages, including algorithm development and feasibility testing, and there is little understanding of how people with chronic conditions view AI’s role in their care.47 To fully realize AI’s potential in this field, especially across different chronic illness populations,7,15,41 it is vital to investigate patient expectations, trust, and worries about AI-driven solutions as eHealth systems15,48 become more integrated.

    Perceived usefulness and ease of use emerged as primary factors affecting users’ willingness to use technology, which is consistent with widely used technology acceptance models.49,50 Patients in this study, especially those with diabetes and hypertension, expected more benefits from such tools in supporting self-management, influenced by some patients’ previous experiences with condition-specific applications. As different groups of patients demonstrate varying needs and requirements in relation to further self-management support, tailoring digital health tools to specific patient groups would likely increase expected benefits. Cultural differences also played a key role in the self-management approach. Participants in this study with diabetes and hypertension said that lack of current dietary food tools for their particular regional meals and a need for culturally specific tools and recommended that advantages of AI-based tools could support such features to adapt a healthy daily routine, helping users manage their condition more confidently and effectively. Therefore, offering culturally appropriate eHealth tools with AI features detecting needs, such as regional meal dishes or culturally relevant dietary recommendations, could significantly increase acceptance and use and manage their condition more confidently and effectively.7,41,51

    Participants in eHealth services also highlight the significance of support from family and friends in influencing their involvement with these services. Especially for individuals less confident with technology, social support offered both emotional motivation and practical assistance. Close social circles’ participation seemed to increase users’ confidence in the services and support their planned use.52,53 Particularly relevant in collectivist societies, such as in many Arab countries, where interpersonal relationships significantly affect individual behavior,32,33 these results correspond with earlier studies indicating that family and peer support may be vital in health-related decision-making and technology adoption.50,54

    The patients’ interest in self-management support appears to be influenced by their perceived control over their disease, which is known as the health locus of control. Research has indicated that individuals with a higher sense of internal control may be more inclined to engage in self-management actions and techniques.2 Further studies should explore the relationship between patients’ perceived control and their willingness to adopt self-management technologies. Many participants expressed anxiety about taking measurements and uncertainty regarding the interpretation of abnormal results, highlighting the need for healthcare professionals to provide clear guidance on using digital health tools and understanding their outcomes.

    The study results emphasized the importance of offering patients’ choices in digital health adoption and clearly explained the implementation benefits. Patients wanted more control over their health despite the more prescriptive character of the Saudi healthcare system, reflecting global trends in patient-centered care.2,26,27 In a system that is usually more structured, this preference complicates the application of eHealth technologies.2

    These results underline the importance of incorporating more flexibility and patient choice in the Saudi healthcare system—especially with regard to artificial intelligence tools—to more closely fit patients’ needs and expectations.2 Users reported few privacy concerns regarding digital health tools but stressed the importance of training and technical support in familiarizing users with tools and overcoming usability issues to enhance acceptance.33 This aligns with previous evidence indicating that diverse users can engage with digital health tools given appropriate training and support.33

    Strengths and Limitations

    The strength of this study is that it is the first that focus on various chronic illness experiences of self-management and patients’ readiness to use digital health in the context of Saudi Arabia and the larger Gulf Region, providing a thorough knowledge of their opinions, needs, and interests, across a more broad spectrum of common chronic diseases. The qualitative methodology also allowed participants to answer and show their need to use their own feelings and opinions in depth rather than select predetermined options.55 The study design, involving eight focus groups, each comprising participants with the same chronic condition, enabled more focused and in-depth discussions on condition-specific experiences, needs, and challenges. However, some limitations have to be considered. First, the generalizability of this study is limited by its focus on a Saudi context and the use of a convenience sample, which may have favored participants more comfortable with technology—potentially excluding those with lower digital literacy, such as individuals with COPD. While most participants had some Internet familiarity, this factor may have influenced their willingness to adopt digital health services,56 as research suggests that computer and Internet proficiency significantly affects technology acceptance.54 Still, the results underline the impact of cultural and contextual elements on digital health uptake and offer insightful analysis for more general eHealth projects. Future studies should investigate comparable patient views in various healthcare settings, hence enabling cross-country comparisons to confirm and broaden these results.

    Conclusions

    This investigation revealed differences in requirements and expectations among patient groups regarding self-management and eHealth support, indicating that digital health and its implementation should be customized for specific individual groups. While those with cardiovascular diseases had the least interest, those with COPD came next in openness to using eHealth technologies behind diabetics and hypertensives. Participants therefore predicted gains and advantages from eHealth, and perceived disease controllability was crucial in determining their willingness to use digital health for self-management purposes. Clear information about eHealth possibilities, usage, and implementation rationale is crucial for encouraging its adoption in primary care settings. However, it is important to acknowledge that not every patient wishes to use digital healthcare services. To improve uptake, involving patients in digital health tool design is essential to ensure that tools meet their needs and preferences, and address usage factors. This patient-centered approach can help create more effective and widely accepted digital health solutions.

    Institutional Review Board Statement

    The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ministry of Health (MOH) approval number 21-518E).

    Data Sharing Statement

    The data presented in this study are not publicly available due to ethical restrictions. However, they are available from the corresponding author upon reasonable request.

    Informed Consent Statement

    Informed consent was obtained from all subjects involved in the study.

    Acknowledgments

    The author would like to acknowledge the assistant researcher (Dr. Musaad Alhumaid) for their invaluable support and assistance with data analysis. The author extends their appreciation for participating in this study.

    Funding

    The authors acknowledge funding from the King Saud University, Deanship of Scientific Research. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

    Disclosure

    The author declares no conflict of interest.

    References

    1. Bahari G, Kerari A, Kerari A. Evaluating the effectiveness of a self-management program on patients living with chronic diseases. Risk Manag Healthc Policy. 2024;1037–1038. doi:10.2147/RMHP.S474013

    2. Al Ahmari K, Sayyar K, Alanazi M, et al. Patient-centered approach in Saudi healthcare system. Sys Rev. 2024;12(3):38–43.

    3. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for people with chronic conditions: a review. Patient Educ Couns. 2002;48(2):177–187. doi:10.1016/S0738-3991(02)00032-0

    4. Jerant AF, Von Friederichs-Fitzwater MM, Moore M. Patients’ perceived barriers to active self-management of chronic conditions. Patient Educ Couns. 2005;57(3):300–307. doi:10.1016/j.pec.2004.08.004

    5. Chen C, Liu A, Zhang Z, Chen J, Huang H. Digital therapeutics in hypertension: how to make sustainable lifestyle changes. J Clin Hypertens. 2024;26(10):1125–1132. doi:10.1111/jch.14894

    6. Eysenbach G. What is e-health? J Med Internet Res. 2001;3(2):e20.

    7. Ansari RM, Harris MF, Hosseinzadeh H, Zwar N. Application of artificial intelligence in assessing the self-management practices of patients with type 2 diabetes. Healthc. 2023;11:903. doi:10.3390/healthcare11060903

    8. Marsch L, Lord S, Dallery J. Behavioral healthcare and technology: using science-based innovations to transform practice. [cited Oct 28, 2024]. Available from: https://books.google.com/books?hl=en&lr=&id=lmnDBAAAQBAJ&oi=fnd&pg=PP1&ots=v4NIEOqVla&sig=c01Eujj2RFZMYcQMzpTLGCRfxDM. Accessed September 11, 2025.

    9. Wade AG. Use of the internet to assist in the treatment of depression and anxiety: a systematic review. Prim Care Companion CNS Disord. 12(4):27390.

    10. Heimer M, Schmitz S, Teschler M, et al. eHealth for maintenance cardiovascular rehabilitation: a systematic review and meta-analysis. Eur J Prev Cardiol. 2023;30:1634–1651. doi:10.1093/eurjpc/zwad145

    11. Yang M, Duan Y, Liang W, et al. Effects of face-to-face and ehealth blended interventions on physical activity, diet, and weight-related outcomes among adults: a systematic review and meta-analysis. Int J Environ Res Public Heal. 2023;20:1560. doi:10.3390/ijerph20021560

    12. Allen M, Iezzoni LI, Huang A, Huang L, Leveille SG. Improving patient-clinician communication about chronic conditions: description of an internet-based nurse E-coach intervention. Nurs Res.

    13. De Jong CC, Ros WJG, Schrijvers G. The effects on health behavior and health outcomes of internet-based asynchronous communication between health providers and patients with a chronic condition: a systematic review. J Med Internet Res. 2024;57(2):107–12.

    14. Paré G, Jaana M, Sicotte C. Systematic review of home telemonitoring for chronic diseases: the evidence base. J Am Med Inf Assoc. 2024;14(3):269–77.

    15. Hwang M, Zheng Y, Cho Y, Jiang Y. AI applications for chronic condition self-management: scoping review. J Med Internet Res. 2025;27(1):27e59632.

    16. Alessa T, Abdi S, Hawley MS, De Witte L. Mobile apps to support the self-management of hypertension: systematic review of effectiveness, usability, and user satisfaction. JMIR mHealth uHealth. 2018;6(7).

    17. Megat Kamaruddin PSN, Mohammed Nawi A, Abdul Manaf MR, Yaman MN, Abd Malek AM. A meta-analysis of eHealth interventions on ischaemic heart disease health outcomes. Glob Heart. 2023;18. doi:10.5334/gh.1173

    18. Alessa T. Clinicians’ attitudes toward electronic health records in Saudi Arabia. Cureus. 2024;16(3):1–10.

    19. May CR, Finch TL, Cornford J, et al. Integrating telecare for chronic disease management in the community: what needs to be done? BMC Health Serv Res. 2011;11(1):1–11. doi:10.1186/1472-6963-11-1

    20. Subramanian U, Hopp F, Lowery J, Woodbridge P, Smith D. Research in home-care telemedicine: challenges in patient recruitment. Telemed J e-Health. 2004;10(2):155–161. doi:10.1089/tmj.2004.10.155

    21. Huygens MWJ, Vermeulen J, Swinkels ICS, Friele RD, Van Schayck OCP, De Witte LP. Expectations and needs of patients with a chronic disease toward self-management and eHealth for self-management purposes. BMC Health Serv Res. 2016;16(1):1–11. doi:10.1186/s12913-015-1254-9

    22. Sanders C, Rogers A, Bowen R, et al. Exploring barriers to participation and adoption of telehealth and telecare within the whole system demonstrator trial: a qualitative study. BMC Health Serv Res. 2012;12(1):1–12. doi:10.1186/1472-6963-12-1

    23. Liu S, Li J, Wan DY, et al. Effectiveness of eHealth self-management interventions in patients with heart failure: systematic review and meta-analysis. J Med Internet Res. 2022;24(9):e38697. doi:10.2196/38697

    24. Shen H, Van Der Kleij RMJJ, Van Der Boog PJM, Chang X, Chavannes NH. Electronic health self-management interventions for patients with chronic kidney disease: systematic review of quantitative and qualitative evidence. J Med Internet Res. 2019;21(11). doi:10.2196/12384

    25. Dabbs ADV, Myers BA, Mc Curry KR, et al. User-centered design and interactive health technologies for patients. CIN – Comput Informatics Nurs. 2009;27(3):175–183. doi:10.1097/NCN.0b013e31819f7c7c

    26. LeRouge C, Wickramasinghe N. A review of user-centered design for diabetes-related consumer health informatics technologies. J Diabetes Sci Technol. 2013;7(4):1039–1056. doi:10.1177/193229681300700429

    27. Vaisson G, Provencher T, Dugas M, et al. User involvement in the design and development of patient decision aids and other personal health tools: a systematic review. Med Decis Mak. 2021;41(3):261–274. doi:10.1177/0272989X20984134

    28. Peeters JM, Wiegers TA, Friele RD. How technology in care at home affects patient self-care and self-management: a scoping review. Int J Environ Res Public Heal. 2013;10:5541–5564. doi:10.3390/ijerph10115541

    29. van Houtum L, Rijken M, Heijmans M, Groenewegen P. Patient-perceived self-management tasks and support needs of people with chronic illness: generic or disease specific? Ann Behav Med. 2015;49(2):221–229. doi:10.1007/s12160-014-9649-0

    30. Wang B, Asan O, Mansouri M. Perspectives of patients with chronic diseases on future acceptance of AI-based home care systems: cross-sectional web-based survey study. JMIR Hum Factors. 2023;10(1):e49788. doi:10.2196/49788

    31. Al-Sulimani TS, Bouaguel W. Understanding factors influencing diabetic patients’ intention to use digital health services in Saudi Arabia using the technology acceptance model. Int J Environ Res Public Heal. 2024;21:889. doi:10.3390/ijerph21070889

    32. Almazroi AA, Mohammed F, Al-Kumaim NH, Hoque MR. An empirical study of factors influencing e-health services adoption among public in Saudi Arabia. Health Informatics J. 2022;28(2). doi:10.1177/14604582221102316

    33. Alessa T, Hawley MS, Alsulamy N, de Witte L. Using a commercially available app for the self-management of hypertension: acceptance and usability study in Saudi Arabia. JMIR mHealth uHealth. 2021;9(2):e24177. doi:10.2196/24177

    34. Mohamed AH, Ghonim M, Somaili M, et al. Patients’ perception towards digital health services in Saudi Arabia: a cross-sectional study. Medicine. 2023;102(50):E36389. doi:10.1097/MD.0000000000036389

    35. Abu-Elenin MM, Jaffery F, Gelal R, Alblaid R, Samarkandi L. The perceptions towards the effectiveness of mHealth applications during the COVID-19 pandemic among Saudi healthcare providers. Perspectives Health Info Manag. 2023;20.

    36. Almalki ZS, Imam MT, Ahmed NJ, et al. The influence of telemedicine in primary healthcare on diabetes mellitus control and treatment adherence in Riyadh region. Saudi Pharm J SPJ off Publ Saudi Pharm Soc. 2024;32(1).

    37. Alzahrani A, Gay V, Alturki R. Exploring saudi individuals’ perspectives and needs to design a hypertension management mobile technology solution: qualitative study. Int J Environ Res Public Heal. 2022;19:12956. doi:10.3390/ijerph191912956

    38. WHO G. Global status report on noncommunicable diseases 2010. [cited October 28, 2024]. Available from: https://www.sidalc.net/search/Record/unfao:674278/Description. Accessed September 11, 2025.

    39. Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–1288. doi:10.1177/1049732305276687

    40. Barlow JH, Sturt J, Hearnshaw H. Self-management interventions for people with chronic conditions in primary care: examples from arthritis, asthma and diabetes. Patient Educ Couns. 61(4):365–378.

    41. Barreveld AM, Rosén Klement ML, Cheung S, et al. An artificial intelligence-powered, patient-centric digital tool for self-management of chronic pain: a prospective, multicenter clinical trial. Pain Med. 2023;24(9):1100–1110. doi:10.1093/pm/pnad049

    42. Bringsvor HB, Langeland E, Oftedal BF, Skaug K, Assmus J, Bentsen SB. Effects of a COPD self-management support intervention: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2018;13:3677–3688. doi:10.2147/COPD.S181005

    43. Bergman L, Nilsson U, Dahlberg K, Jaensson M, Wångdahl J. Health literacy and e-health literacy among Arabic-speaking migrants in Sweden: a cross-sectional study. BMC Public Health. 2021;21(1):1–12. doi:10.1186/s12889-021-12187-5

    44. Althobiani MA, Russell AM, Jacob J, et al. The role of digital health in respiratory diseases management: a narrative review of recent literature. Front Med. 2025;12:1361667. doi:10.3389/fmed.2025.1361667

    45. Alghamdi SM, Al Rajah AM, Aldabayan YS, Aldhahir AM, Alqahtani JS, Alzahrani AA. Chronic obstructive pulmonary disease patients’ acceptance in e-health clinical trials. Int J Environ Res Public Health. 2021;18:5230. doi:10.3390/ijerph18105230

    46. Alzghaibi H. Adoption barriers and facilitators of wearable health devices with AI integration: a patient-centred perspective. Front Med. 2025;12:1557054. doi:10.3389/fmed.2025.1557054

    47. Pan M, Li R, Wei J, et al. Application of artificial intelligence in the health management of chronic disease: bibliometric analysis. Front Med. 2025;11:1506641. doi:10.3389/fmed.2024.1506641

    48. Hassan N, Slight R, Bimpong K, et al. Systematic review to understand users perspectives on AI-enabled decision aids to inform shared decision making. Npj Digit Med. 2024;7(1):1–11. doi:10.1038/s41746-023-00987-5

    49. Davis F, Bagozzi R, Sci PW-JM. U. technology acceptance model. J Manag Sci. 1989.

    50. Venkatesh V, Morris M, Davis G, Quarterly FD-M. U. User acceptance of information technology: toward a unified view. 2003 [cited Oct 28, 2024]; Available from.: https://www.jstor.org/stable/30036540. Accessed September 11, 2025.

    51. Alnooh G, Alessa T, Noorwali E, et al. Identification of the most suitable mobile apps to support dietary approaches to stop hypertension (DASH) diet self-management: systematic search of app stores and content analysis. Nutrients. 1989.

    52. Kim BR, Jeong CH, Blood E, et al. Multilevel factors influencing eHealth adoption among older adults during the pandemic. Front Public Health. 2025;15(15):3476.

    53. Alessa T, Alhussaini K, de Witte L. Assessing patient use of and attitudes toward eHealth services for communication with primary care centers in Saudi Arabia and factors affecting usage. Healthc. 2025;13:1531173

    54. CKL O, Karsh BT. A systematic review of patient acceptance of consumer health information technology. J Am Med Inf Assoc. 2024;16(4):550–560.

    55. Mack N, Hua F, Mack N. Qualitative research methods: a data collector’s field guide. Optics Express. 2005;13(15):5669–5675. doi:10.1364/opex.13.005669

    56. Talboom-Kamp EPWA, Holstege MS, Chavannes NH, Kasteleyn MJ. Effects of use of an eHealth platform e-Vita for COPD patients on disease specific quality of life domains. Respir Res. 2019;20. doi:10.1186/s12931-019-1110-2

    Continue Reading

  • Norwegian Launches Summer 2026 Schedule and increase routes to the UK

    Norwegian Launches Summer 2026 Schedule and increase routes to the UK

    Norwegian has released tickets for its summer 2026 programme, offering travellers an extensive network of over 300 routes to more than 120 destinations across Europe. The schedule, covering the period from March to October 2026, is now available for booking.

    The airline continues to strengthen its presence in the UK, with direct year-round flights from London, Manchester, Edinburgh, and Newcastle to Nordic capitals and key cities.

    “In our summer 2026 schedule, we’ve increased capacity and expanded our offering to the Nordic region, giving both leisure and business travellers even more choice,” said Magnus Thome Maursund, Chief Commercial Officer at Norwegian.

    The Nordic countries remain a popular destination for British travellers, known for their stunning natural landscapes and outdoor activities such as hiking, kayaking, sailing, climbing, and skiing – both on-piste and off-piste.

    UK Departures and Destinations

    From London (Gatwick) direct to:

    • Norway: Ålesund, Bergen, Oslo, Stavanger, Trondheim
    • Denmark: Billund, Copenhagen
    • Sweden: Gothenburg, Stockholm
    • Finland: Helsinki

    From Manchester direct to:

    • Norway: Oslo, Stavanger, Bergen
    • Denmark: Copenhagen
    • Sweden: Stockholm

    From Edinburgh direct to:

    • Norway: Bergen, Copenhagen, Oslo, Stockholm

    From Newcastle direct to:

    The full summer 2026 schedule includes routes across Norwegian’s core markets, with approximately 90 aircraft in operation – many of which are the new, fuel-efficient Boeing 737 MAX 8. These modern aircraft offer a more comfortable travel experience while reducing fuel consumption and emissions.

    Continue Reading